NCT07431593 Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications
| NCT ID | NCT07431593 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rijeka |
| Condition | Overweight and Obesity |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-04 |
| Primary Completion | 2027-04-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-04 with a primary completion date of 2027-04-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.
Eligibility Criteria
Inclusion Criteria * Age ≥ 18 years * BMI 25.0-29.9 kg/m² (overweight) or BMI ≥ 30 kg/m² (obesity) * Ability to attend scheduled clinical visits * Willingness to provide informed consent Exclusion Criteria * Pregnancy or breastfeeding * Use of immunosuppressive therapy * Active infection * Inflammatory disease * Malignancy * Acute illness affecting immune parameters * Conditions interfering with study participation (as assessed by the investigator) * Known hematologic disorders affecting leukocyte or platelet counts * Chronic inflammatory diseases requiring systemic therapy * Recent major surgery (within the last 3 months) * Any condition that could confound the relationship between SII/SIRI and obesity-driven inflammation, such as immune disorders
Contact & Investigator
Gordana Kenđel Jovanović, Asst. Prof.
PRINCIPAL INVESTIGATOR
Faculty of Medicine, University of Rijeka
Frequently Asked Questions
Who can join the NCT07431593 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Overweight and Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07431593 currently recruiting?
Yes, NCT07431593 is actively recruiting participants. Contact the research team at gordanakj@uniri.hr for enrollment information.
Where is the NCT07431593 trial being conducted?
This trial is being conducted at Varaždin, Croatia.
Who is sponsoring the NCT07431593 clinical trial?
NCT07431593 is sponsored by University of Rijeka. The principal investigator is Gordana Kenđel Jovanović, Asst. Prof. at Faculty of Medicine, University of Rijeka. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.